// App-Quantinova.ai

499 : Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).

Researchers

Presenter

  • Bernard J. Escudier

Principal Investigators

  • Thomas Powles

  • Nizar M. Tannir

  • Ian D. Davis

  • Frede Donskov

  • Viktor Grnwald

  • Daniel Yick Chin Heng

  • Thomas Hutson

  • Bohuslav Melichar

  • Dimitry Nosov

  • Brian I. Rini

  • Pamela Salman

  • Cora N. Sternberg

  • Cezary Szczylik

  • Pascal Wolter

  • Alan M Arroyo

  • Milan Mangeshkar

  • Neeraj Agarwal

  • Toni K. Choueiri

Medical Centers

  • Institut Gustave-Roussy, Villejuif, France

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Barts Cancer Institute, Barts Health, and The Royal Free London NHS Foundation Trust, London, United Kingdom

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Monash University Eastern Health Clinical School, Melbourne, Australia

  • Department of Hematology, Aarhus University Hospital, Aarhus, Denmark

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Onkologicka Klinika, Lekarska Fakulta Univerzity Palackeho a Fakultni Nemocnice, Olomouc, Czech Republic

  • Blokhin Oncology Research Center, Moscow, Russia

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Fundacion Arturo Lopez Perez, Santiago, Chile

  • San Camillo-Forlanini Hospital, Rome, Italy

  • Department of Oncology, Military Institute of Medicine, Warsaw, Poland

  • University Hospital Leuven, Department of General Medical Oncology, Leuven, Belgium

  • Exelixis, Inc, South San Francisco, CA

  • Exelixis, Inc, South San Francisco, CA

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • France

  • United States

  • United Kingdom

  • Australia

  • Denmark

  • Germany

  • Canada

  • Czech Republic

  • Russia

  • Chile

  • Italy

  • Poland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • Kinase Insert Domain Receptor

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Cabozantinib

  • Everolimus

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01865747

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved